A Phase 2 Study of Brentuximab Vedotin With Chemotherapy in People With T-Cell Lymphoma

Full Title

A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients with CD30-Positive Peripheral T-cell Lymphomas

Purpose

Brentuximab vedotin (BV) plus chemotherapy with the drugs cyclophosphamide, doxorubicin, and prednisone (CHP) is a standard treatment for T-cell lymphomas that make the CD30 protein. Researchers want to see if BV with an enhanced chemotherapy regimen that includes etoposide works better in people with T-cell lymphomas.

The people in this study have T-cell lymphoma that has not yet been treated and makes CD30. The drugs in this study are given intravenously (by vein).

Contact

For more information or to see if you can join this study, please call Dr. Robert Stuver’s office at 646-608-4308.